Gaithersburg, MD and Cambridge, UK- MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Cambridge have entered into a research collaboration that aims to use imaging technologies to measure key biological changes within drug-treated tumours.

The work will be undertaken in the Cancer Research UK Cambridge Institute, situated on the Addenbrooke's Biomedical Campus in Cambridge.  

As part of the University of Cambridge School of Clinical Medicine, the Institute's aims are to link the laboratory to the clinic with a multi-disciplinary approach to cancer-focussed research.  The Institute currently houses over 350 researchers and support staff with 20 research groups. It provides a highly collaborative, multi-disciplinary environment in cancer research, with state of the art facilities and core scientific resources, and good links with the scientific community of Cambridge.

A major interest of the institute is the development of novel imaging methods and their translation to the clinic.  We are seeking to appoint a highly motivated individual with experience in protein chemistry and an interest in tumour biology and imaging to a post-doctoral position in the laboratory of Prof. Kevin Brindle FMedSci.  The post is available immediately and would be for 3 years in the first instance.

The successful candidate will hold a PhD and should ideally have experience in recombinant DNA techniques and protein chemistry.  An interest in tumour biology, preferably in the area of imaging, is desirable although not essential.